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Abstract
Objectives: To determine the health and economic burdens of post-partum Staphylococcus aureus breast abscess.
Study design: We conducted a matched cohort study (N = 216) in a population of pregnant women (N= 32,770) who
delivered at our center during the study period from 10/1/03–9/30/10. Data were extracted from hospital databases, or via
chart review if unavailable electronically. We compared cases of S. aureus breast abscess to controls matched by delivery
date to compare health services utilization and mean attributable medical costs in 2012 United States dollars using
Medicare and hospital-based estimates. We also evaluated whether resource utilization and health care costs differed
between cases with methicillin-resistant and -susceptible S. aureus isolates.
Results: Fifty-four cases of culture-confirmed post-partum S. aureus breast abscess were identified. Breastfeeding cessation
(41%), milk fistula (11.1%) and hospital readmission (50%) occurred frequently among case patients. Breast abscess case
patients had high rates of health services utilization compared to controls, including high rates of imaging and drainage
procedures. The mean attributable cost of post-partum S. aureus breast abscess ranged from $2,340–$4,012, depending on
the methods and data sources used. Mean attributable costs were not significantly higher among methicillin-resistant vs. –
susceptible S. aureus cases.
Conclusions: Post-partum S. aureus breast abscess is associated with worse health and economic outcomes for women and
their infants, including high rates of breastfeeding cessation. Future study is needed to determine the optimal treatment
and prevention of these infections.
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Introduction
Mastitis, most often caused by Staphylococcus aureus [1,2,3], occurs
in approximately 20% of breastfeeding mothers and may be a
precursor to the development of breast abscess [4,5,6,7]. S. aureus is
also the predominant pathogen in post-partum breast abscess
[8,9,10], and rates of methicillin-resistant S. aureus (MRSA) have
increased in the pregnant and post-partum population [10,11,12].
Although breast abscess is a serious, uncommon complication of
mastitis with high morbidity [13,14], health services utilized by
patients with these infections have been poorly characterized.
Neither the clinical outcomes, such as milk fistula formation and
rates of breastfeeding cessation, nor the attributable medical costs
of these infections are known. Further, it is unknown if the
emergence of MRSA has worsened outcomes and increased health
services utilization and medical cost.
The aims of this study were to: (1) characterize the health and
economic outcomes of patients with post-partum S. aureus breast
abscess, suchasbreastfeeding cessation, developmentofmilk fistulae,
rates of adverse reactions to antibiotics, rates of health service
utilization andmedical costs and (2) explore whether costs are higher
for MRSA vs. methicillin-susceptible S. aureus (MSSA) infections.
Methods
Setting
We conducted a population-based matched cohort study among
post-partum women who delivered at Beth Israel Deaconess
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Medical Center (BIDMC), an academic tertiary care center with
approximately 4,750 deliveries per year, between 10/1/2003–8/
31/2010. From 10/2008–3/2010, a cluster of pulse-field type
USA300–0114 MRSA infections in post-partum women and their
infants who delivered at our center were identified; the majority of
infections in mothers were mastitis and breast abscesses [10,15,16].
Cluster cases were defined as onset of MRSA post-partum breast
abscess within one year after delivery.
Case and Control Selection
Cases were defined as any woman with a culture-confirmed S.
aureus breast abscess within one year after delivery identified via
needle drainage, incision and drainage, operative intervention, or
spontaneous drainage. Women with uncomplicated infectious
mastitis as well as a prior history of any S. aureus infection were
excluded from the case definition.
We selected population-based controls of pregnant women who
delivered at our center (N= 32,770). Exclusion criteria for control
selection included pre-partum breast abscess, neonatal demise
within 24 hours of delivery, stillbirth, and culture-confirmed S.
aureus infection at another body site. Controls were matched to
cases in a 3:1 fashion by delivery date to minimize potential bias
due to secular trends in diagnosis or management of breast
abscesses. Controls with a history of any prior S. aureus infection
were excluded from the case-control analysis.
Data Collection
Hospital databases (Infection Control, Microbiology, Obstetrics,
Admission Discharge Transfer, Fiscal databases) were used to
extract data for the full population-based cohort, including
inpatient admissions, laboratory tests, and radiologic studies. If
hospital cost data were not available, we estimated components of
medical costs using the Medicare Fee schedule [17,18].
Additional variables not available electronically were abstracted
via medical record review for matched cohort study patients for up
to one year after delivery or at the first visit for a subsequent
pregnancy, whichever came first. Information was collected on
follow-up outpatient visits to obstetrics and gynecology, internal
medicine, dermatology, infectious diseases and allergy. Additional
information was also collected about relevant radiographic studies
(breast ultrasounds, mammograms, and breast magnetic resonance
imaging), laboratory testing (complete blood counts (CBC),
chemistries, wound and blood cultures), pathology (breast biopsy),
central venous catheter placement, and antibiotic use and type,
including use of outpatient intravenous antibiotics.
Overall hospital readmission rates were collected for the entire
birth cohort. Associated adverse outcomes were extracted via chart
review for matched cohort study patients only (breastfeeding
cessation, milk fistula formation, and adverse effects of antibiotic
use (rash, allergy)).
Data Analysis
Health outcomes, health services utilization, and medical costs
were evaluated for both the full cohort and the matched cohort.
Descriptive analyses were performed using proportions, means,
and medians. We compared rates of outcomes, health service
utilization and costs using Wilcoxon rank-sum or Chi-squared tests
as appropriate.
To maximize accuracy and generalizability, the attributable
medical cost of post-partum S. aureus breast abscess was estimated
in three ways (Table 1). First, total direct medical costs for cases
and non-cases in the overall cohort were estimated from hospital
fiscal databases with attributable medical costs calculated as the
difference between cases and non-cases and averaged across the
entire cohort. A second approach was based on estimating the
difference in direct medical costs, based on hospital fiscal
databases, only for those services potentially associated with S.
aureus breast abscess (i.e., readmission, outpatient visits, laboratory
testing, and radiology) for cases and non-cases in the overall
cohort. Indirect medical costs, such as facility costs including
overhead costs and equipment costs, were not available for
analysis.
Finally, a third approach to estimating attributable total medical
costs in the matched cohort study used national estimates of costs
for each unit of health service utilization. The attributable costs
were then calculated using the difference in the costs for cases
versus controls, averaged across the matched cohort population.
More specifically, each unit of service (e.g., hospitalization,
procedures, laboratory and radiographic testing, outpatient visits)
was multiplied by the cost of the unit of service based on the
Medicare Fee Schedule and the Physician Fee Schedule [17,18].
Laboratory costs were based on maximum Centers for Medicare
and Medicaid Services reimbursement rates. Medication costs
were estimated using the average wholesale price from the
pharmacy Red Book [19] multiplied by the number of pills
required to complete a standard antibiotic course.
Medical costs were adjusted to 2012 dollars using the medical
aspect of the gross domestic product deflator, available from the
United States Bureau of Labor Statistics [20]. Attributable cost
was calculated by determining the mean medical cost of cases and
subtracting the mean medical cost of control patients.
Pre-specified sub-analysis. We compared health services
utilization and medical costs in case patients with MSSA to case
patients with MRSA using descriptive statistics, as outlined above.
A p-value of ,0.05 was considered statistically significant. Data
were analyzed using SAS version 9.3 (SAS Institute, Cary NC).
Ethical Considerations
Institutional Review Board approval from BIDMC was
obtained prior to data collection and analysis. Due to the
retrospective study design, and acquisition of data through medical
record review, waiver of informed consent was granted.
Results
Study Population
A total of 32,770 women delivered at our center during the
study period. The mean maternal age among all women delivering
at our center was 32.4 years, and 48.1% were primiparous.
Baseline demographic description of the entire cohort including
the 54 cases and 162 matched controls as well as the epidemic
curve were previously published [10]. The cases included were 30
patients with MRSA abscess and 24 with MSSA breast abscess.
The median time to diagnosis of S. aureus breast abscess after post-
partum discharge was 34 days (Interquartile range (IQR), 24–
49 days). There was no effect of MRSA or cluster period on time
to clinical diagnosis.
During the cluster period (10/2008–3/2010), a total of 31
patients were diagnosed with culture-confirmed S. aureus breast
abscess; 6 with MSSA infection and 25 with MRSA infection. The
predominant MRSA strain found during the cluster period was
pulsed-field type USA 300–0114 (data not shown) [15,16].
Of the full cohort of 32,770 deliveries, 98.2% (32,188/32,770)
returned to our center for any type of care during the one-year
period following delivery. Among patients enrolled in the matched
cohort study, 98.6% (213/216) patients received care at our
facility during the one-year period after delivery.
Health and Economic Burden of Breast Abscess
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Outcomes
Matched cohort study. The readmission rate among case
patients was 50%, compared to less than 2% among control
patients (Table 2). The overall rate of breastfeeding cessation
among breast abscess cases was 41%, and did not differ between
MRSA and MSSA infections (Table 3). Data regarding breast-
feeding cessation was unavailable for control patients.
Among all breast abscess cases, six patients developed milk
fistulae. The rate of breastfeeding cessation among milk fistula
cases was high (66.7%) but not significantly different from all other
breast abscess cases.
Health Services Utilization
Full cohort. The overall rate of readmission among patients
in the full cohort who returned to our center (N= 32,188) was
3.2%, and in cases (N= 54), 50% (p,0.0001).
Matched cohort study. Cases in the matched cohort study
had significantly higher rates of physician visits, radiology
utilization and antibiotic utilization than controls without post-
partum breast abscess (Table 2). Across all cases, the median
number of ultrasounds per patient was 3.5, range 0–17. Forty-one
percent of cases (22/54) had greater than or equal to five breast
ultrasounds. For controls, the median number of breast ultra-
sounds was zero. The rate of mammography was similar in case
and control patients. No patients in the matched cohort study
received breast magnetic resonance imaging.
The majority (75.9%) of the 54 breast abscess cases were treated
with needle-guided drainage [21,22,23]. The median number of
drainage procedures was two (interquartile range, 1.0–4.0), with a
maximum of 15 drainage procedures in one patient. Thirteen
(24%) required greater than or equal to five drainage procedures.
Six (11%) had surgical incision and drainage; one occurred in the
operating room. 14.8% of case patients (8/54) had spontaneous
abscess drainage.
Antibiotic utilization was available for 92.5% (50/54) case
patients. Ninety-eight percent (49/50) of case patients received
antimicrobial therapy. In total, 16 different types of antibiotics
were prescribed, including two (doxycycline, linezolid) that have
Table 1. Cost Estimate Methodologies.
Total Hospital Direct Cost Partial Hospital Direct Cost Medicare Cost Estimate
Time period One year One year One year
Basis for estimate Hospital fiscal database Hospital fiscal database HSU x Cost per service1
Inpatient direct medical costs included2 All Potentially relevant Disease-attributable
Inpatient indirect medical costs included3 No No Yes
Outpatient costs included4 All Potentially relevant Disease-attributable
Outpatient indirect medical costs included No No Yes
Medication costs included Some Some All
1HSU=Health services utilization. Cost per service based on Medicare Fee Schedules.
2Direct medical costs include those directly related to services provided, such as inpatient stay, outpatient office visits, laboratory and radiographic testing.
3Indirect medical costs include facility operating costs, such as building costs, electricity costs, and costs of equipment.
4‘‘All’’ indicates that all direct medical costs, including those that may not be related to a diagnosis of post-partum breast abscess were included in the estimate of cost.
‘‘Potentially relevant’’ indicates that only direct medical costs related to potentially relevant services (such as visits to internal medicine, obstetrics, infectious diseases,
and radiology) were included in the estimate of cost. ‘‘Disease-attributable’’ indicates that only services attributable to the diagnosis of post-partum breast abscess were
included in the estimate of cost.
doi:10.1371/journal.pone.0073155.t001
Table 2. Health Services Utilization and Clinical Outcomes Among Women During the Year After Post-Partum Discharge: Matched
Cohort Study Results.
Breast Abscess Cases (N= 54) Controls (N = 162) P-value1
Outcomes
Readmission Rate 50% 1.9% ,0.0001
Resource Utilization
Total Number of Drainage Procedures (Median, IQR) 2 (1–4) 0 (0–0) ,0.0001
Antibiotic Utilization 2 86.0% 5.6% ,0.0001
Breast Surgery Consultation 53.7% 0.6% ,0.0001
Infectious Diseases Consultation 35.2% 0.6% ,0.0001
Readmission Length of Stay (Median, IQR) 1 (0–5.5) 0 (0–0) ,0.0001
Number of Breast Ultrasounds (Median, IQR) 3.5 (2–6) 0 (0–0) ,0.0001
Outpatient Office Visits 3 (Median, IQR) 5 (2–7) 0 (0–0) ,0.0001
1Wilcoxon rank-sum test, Fisher’s exact test or Chi square test used as appropriate.
2During the one-year period following post-partum discharge. Includes oral and intravenous antibiotics.
3Includes relevant office visits to obstetrics and gynecology (excluding routine post-partum care, preventive care, and visits for contraception), infectious diseases,
breast surgery, internal medicine, and dermatology. No patients in the matched cohort study had allergy/immunology outpatient visits.
doi:10.1371/journal.pone.0073155.t002
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unsafe or unknown safety profiles in breastfeeding women [24,25].
Trimethoprim-sulfamethoxazole was prescribed frequently during
the cluster period with a high rate of MRSA infections. 79.5%
(39/49) patients were initially treated with a beta-lactam
antibiotic, including 60% (18/30) patients ultimately diagnosed
with MRSA infection.
Among the six patients who developed milk fistulae, there was a
significantly higher rate of breast surgery consultations (6/6, 100%
versus 23/48, 47.9%, p= 0.025), number of outpatient physician
visits [median 8.5 (IQR, 6.0–15.0) versus median 4.0 (IQR, 2.0–
7.0), p = 0.016], and outpatient parenteral antibiotic utilization (2/
6, 33.3% versus 1/48, 2.1%, p= 0.030). There was a trend toward
increased rates of surgical incision and drainage procedures (33%
versus 9.3%, p= 0.089), number of breast ultrasounds [median 4.5
(IQR, 3.0–7.0) versus 3.0 (IQR, 1.5–6.0), p = 0.29], and number of
antibiotics prescribed (3.2 versus 2.4, p = 0.080) among case
patients who developed milk fistulae and those who did not.
Costs
For the entire cohort, the mean attributable cost based on total
direct medical cost was $2,414 (95% CI, $1,458–$3,370) and
$2,340 (95% CI, $2027–$2610) based on only including potentially
relevant services (Table 4).
In the matched cohort study, the attributable cost estimate for
the matched cohort study ranged from a minimum in the partial
direct facility costs of $2386 (95% CI, $2,027–$2,745) to a
maximum estimate based on Medicare cost of $4,012 (95% CI,
$3,443–$4,581) (Table 4).
MRSA vs. MSSA Cases
Outcomes. Approximately 11% (6/54) of post-partum breast
abscess cases developed milk fistulae; five patients with MRSA
(17%) and one patient with MSSA (4%). In total, 5/54 patients
(9.3%) of patients had allergic reactions to antibiotic therapy. All
allergic reactions occurred in patients with MRSA infection (5/30,
16.7%) versus MSSA infection (0/24, 0%), however, this
difference did not reach statistical significance (p= 0.06)
(Table 3). Allergic reactions to antibiotic therapy were primarily
due to the use of trimethoprim-sulfamethoxazole and vancomycin
in patients with MRSA.
Health services utilization. Health services utilization was
similar among case patients with MRSA and MSSA breast
abscesses (Table 3); however, MRSA cases had significantly more
outpatient visits (median 6.0 versus 3.0) and a higher proportion of
infectious diseases consultations (57% versus 8.3%, p,0.0001).
There were no significant differences in readmission rates or
duration of readmissions between MRSA and MSSA cases.
Among MRSA cases, there was a trend toward a higher rate of
outpatient parenteral antibiotic therapy (10% versus 0%) and
number of different antibiotics prescribed (2.6 versus 2.1);
however, these differences were not statistically significant.
Costs. Despite an increase in both physician visits and
antimicrobial usage, there was no significant cost difference
between patients with MRSA infection and those with MSSA
infection, or between patients who had milk fistulae compared to
those who did not (Table 5). Attributable costs were similar
regardless of methodology used.
Discussion
Our study is the first to comprehensively evaluate the outcomes
and health and economic burdens of post-partum S. aureus breast
abscess. In general, we found that the consequences of this
infection in a generally healthy population are substantial.
According to ambulatory medical records, many women who
developed post-partum breast abscess chose to stop breastfeeding
due to their infection (41%). In addition, a high proportion of
patients with post-partum S. aureus breast abscess required
inpatient readmission (50%) and treatment with intravenous
antibiotics. Patients with MRSA breast abscess showed a trend
towards increased allergic reactions to antibiotic therapy due to
the prevalent use in this group of trimethoprim-sulfamethoxazole
and vancomycin, drugs that have been associated with among the
highest estimated number of emergency department visits per
10,000 outpatient prescriptions [26]. Notably, in the same study
sulfonamide use was associated with a significantly higher rate of
moderate-to-severe allergic reactions, compared with all other
antibiotic classes combined (4.3% [95% CI, 2.9%–5.8%] vs. 1.9%
[95% CI, 1.5%–2.3%]) [26].
In the BIDMC cohort, the majority of patients received
ultrasound-guided drainage for definitive management of their
infection rather than open drainage. Multiple previous studies
have demonstrated the safety and efficacy of ultrasound-guided
needle drainage in the management of breast abscess
[21,22,27,28,29], and that MRSA infections can be successfully
treated with needle drainage [14]. Few patients (6/45) in our study
required surgical incision and drainage for management, and only
one required incision and drainage in the operating room, which is
similar to rates in previous studies [23,30]. A significant proportion
of patients in our study required five or more drainage procedures,
and some up to 17 prior to resolution, which is higher than has
been found in other studies [23,30,31]. There was no association
between MRSA infection and requirement for additional drainage
procedures, which is consistent with findings in other investiga-
tions [14].
We found no association between surgical incision and milk
fistula formation. In fact, five of the six patients who developed
milk fistulae underwent ultrasound-guided needle aspiration of
their abscesses only; prior work has demonstrated that milk fistulae
occur rarely in this setting [29,32,33].
The attributable medical cost of post-partum S. aureus breast
abscess was high, and in the same range as other post-partum
infections, including surgical site infection after Cesarean delivery
($3761, 95% CI, $3309–$4275) and post-partum endometritis
($4216, 95% CI, $3710–$4792). Medical costs were also similar to
surgical site infections following breast surgery ($4967, 95% CI,
$3447–$6719), all adjusted to 2012 dollars [34,35].
To estimate medical cost, we utilized multiple methods,
including an evaluation of total hospital direct cost, partial
hospital direct cost, and a Medicare-based cost estimation to
improve the accuracy and generalizability of our findings; all
methods yielded similar results. The hospital-based estimates of
cost may have been lower than the Medicare cost estimate because
indirect hospital costs were not available for inclusion in the
analysis (Table 1).
Interestingly, despite the fact that MRSA cases had significantly
more outpatient visits and a higher proportion of infectious
diseases consultations, as well as trends toward a higher rate of
outpatient parenteral antibiotic therapy and allergic reactions to
antibiotic treatment, we found no increase in cost associated with
MRSA breast abscess when compared to MSSA infection, perhaps
due to limited power to detect a difference between the two
groups. Alternatively, outpatient management of these infections
may have averted more costly readmissions or procedures [36].
MRSA patients and MSSA patients did not differ significantly in
rates of readmission and readmission length of stay. Our results
should be viewed in the context of published data on other types of
S. aureus infections that have yielded inconsistent results as to the
Health and Economic Burden of Breast Abscess
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importance of methicillin-resistance in changing economic costs
[37,38,39]; [40].
Limitations
All data were collected from a single large birth cohort at a
tertiary academic referral center and thus included patients with
the most severe complications of post-partum breast abscess, such
as milk fistulae. Thus, our experiences and cost analysis may not
be generalizable to all practices or settings. To improve the
generalizability of our findings, we used multiple methods to
estimate attributable medical costs, including an evaluation of total
and partial direct hospital costs, as well as an analysis using
Medicare estimates. Medicare costs are not directly applicable to a
post-partum population; however, Medicare reimbursement has
been used in many analyses of healthcare costs [17,18]. Although
practices may have changed during the study period, all cases were
matched to contemporary controls, which should control for
changes in hospital practice.
The patients included in our study were all women of
childbearing age, a traditionally young and healthy population.
Our prior work demonstrated that the effect of maternal age on
risk of post-partum breast abscess in the BIDMC cohort was very
Table 3. Health Services Utilization and Clinical Outcomes: Comparing MRSA to MSSA Cases of Post-partum Staphylococcus aureus
Breast Abscess During the Year after Post-Partum Discharge.
MRSA (N=30) MSSA (N= 24) P-value1
Outcomes
Readmission Rate 46.7% 54.2% 0.78
Milk Fistula Formation 16.7% 4.2% 0.21
Breastfeeding Cessation2 50% 29.2% 0.25
Allergic Reaction to Antibiotic3 16.7% 0% 0.059
Resource Utilization
Total Number of Drainage Procedures (Median, IQR) 2.0 (1.0–4.0) 1.0 (1.0–5.0) 0.87
Antibiotics Prescribed (Mean, 95% CI) 2.64 (2.20–3.08) 2.09 (1.71–2.48) 0.064
Breast Surgery Consultation 60% 45.8% 0.41
Infectious Diseases Consultation 56.7% 8.33% ,0.0001
Readmission Length of Stay, Days (Median, IQR) 0.0 (0.0–6.5) 2.5 (0.0–4.0) 0.49
Number of Breast Ultrasounds (Median, IQR) 4.5 (2.0–6.0) 3 (2.0–5.5) 0.35
Outpatient Office Visits (Median, IQR)4 6.0 (4.0–8.5) 3.0 (1.0–6.0) 0.0019
1Wilcoxon rank-sum test, Chi-square, or Fisher’s Exact Test used as appropriate.
2Data missing for 5/54 patients.
3Includes only severe adverse allergic reactions, including hives and severe skin rash. Minor complications excluded.
4Includes relevant office visits to obstetrics and gynecology (excluding routine post-partum care, preventive care, and visits for contraception), infectious diseases,
breast surgery, internal medicine, and dermatology. No patients in the matched cohort study received allergy and immunology outpatient visits.
doi:10.1371/journal.pone.0073155.t003
Table 4. Healthcare Costs of Post-partum Staphylococcus aureus Breast Abscess Compared to Non-infected Controls.
Matched Cohort (N=216)
Cases Controls Difference P-value
Total Hospital Direct Costs1 (Mean, 95% CI) $2809 (2148–3470) $240 (150–330) $2569 (2162–2,976) ,0.0001
Partial Hospital Direct Costs2 (Mean, 95% CI) $2515 (1908–3122) $129 (73–185) $2,386 (2,027–2,745) ,0.0001
Costs based on health service utilization3
(Mean, 95% CI)
$4073 (3097–5049) $61 (21–142) $4,012 (3,443–4,581) ,0.0001
Total Cohort (N=32,188)
Cases Controls Difference P-value
Total Hospital Direct Costs1 (Mean, 95% CI) $2809 (2148–3470) $395 (356–434) $2414 (1458–3370) ,0.0001
Partial Hospital Direct Costs2 (Mean, 95% CI) $2515 (1908–3122) $175 (164–186) $2,340 (2,070–2,610) ,0.0001
Costs based on health service utilization3
(Mean, 95% CI)
– – – –
1Includes all direct healthcare costs based on hospital fiscal databases during the one-year period following post-partum discharge.
2Includes only potentially relevant healthcare costs based on hospital fiscal databases, such as inpatient readmission, relevant outpatient office visits, radiology, and
laboratory costs.
3Estimated by multiplying the number of units of each relevant healthcare service by Medicare reimbursement for each service.
doi:10.1371/journal.pone.0073155.t004
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small (OR 1.08 per year), therefore, we did not control for age as a
potential confounder in medical cost in this generally young and
healthy population [10].
During our study period, there was a large cluster of healthcare-
associated, community-onset infections with MRSA USA300-
0114. As there was no significant difference in overall health
services utilization or medical cost between MRSA and MSSA
cases, this likely did not affect our overall findings. However, our
results may not be reflective of all MRSA infections, but USA300-
0114 MRSA infections in particular.
Additionally, although 98.2% of the patients evaluated in our
study followed up at our center, we did not have complete follow
up data on the entire cohort. It is therefore possible that some
health services utilization and costs were not included. Further, in
our evaluation of total and partial direct costs, we only included
patients with follow up at our center.
Conclusions
Post-partum S. aureus breast abscess frequently led to breastfeed-
ing cessation and was associated with additional poor patient
outcomes, high health services utilization, and significant attrib-
utable medical costs; the economic burden was similar for MRSA
and MSSA infections.
Prevention efforts should be focused on prevention of all types of
S. aureus breast abscess – not just MRSA. Further investigation is
warranted to determine the optimal means of preventing S. aureus
breast infections during the post-partum period.
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